Raguvaran Raja¹*, Kaveri Jambhagi¹, Narayani Yadav¹, Debabrata Mondal¹ and Karikalan Madhesh², Rohit Kumar³ and Med Ram Verma⁴

¹Division of Medicine, ICAR-IVRI, INDIA
²CWL section, ICAR-IVRI, INDIA
³Division of Surgery, ICAR-IVRI, INDIA
⁴Head, Division of Design of Experiments, ICAR-IASRI, INDIA

*Corresponding Author: Raguvaran Raja, Division of Medicine, ICAR-IVRI, India

Received: October 31, 2023 Published: January 24, 2024

Abstract

Background: Immunosuppressant is the mainstay of treatment in canine pemphigus infection and often the treatment is of chronic course in nature. Prolonged use of immunosuppressant leads to various adverse effects.

Objective: There is a need to study the comparative efficacy of immunosuppressant agents in canine pemphigus complex.

Methods: Dogs presented with clinical signs suggestive of pemphigus complex were enrolled into the study and diagnosed based on the acantholytic cells evidence in the cytology of skin impression smear and histomorphology. Dogs were randomly divided into two groups. Gr.1 was treated with Prednisolone @ 2mg/Kg PO (dose tapered later once in every 7 days for 3 weeks) and Gr. II was treated with Cyclosporine @ 5 mg/Kg PO for 3 weeks. Dogs were monitored for resolution of clinical signs and hematobiochemical changes during therapy.

Results: Prednisolone treated dogs showed faster response in contrast to cyclosporine group but, recurrence of clinical signs was noticed in few dogs when the dose was tapered. But, cyclosporine treated dogs responded favourably with mild gastric discomfort without any changes in the liver and kidney function markers. There was no significant difference in the complete blood count and vital organs markers (BUN, Creatinine, SGPT, and ALP) before and after therapy except blood glucose level.

Conclusion: Cyclosporine treated dogs responded favourably as compared to prednisolone treated dogs

Keywords: Cyclosporine; Dogs; Immunosuppressant; Pemphigus; Prednisolone

References

1. Miller WH., et al. “Muller and Kirk’s Small Animal Dermatology”.7^th St. Louis, Missouri: Elsevier (2013).
2. Fentahun WM., et al. “Common Immune mediated Skin Diseases of Dog”. Advances in Biotechnology and Microbiology 1 (2016): 555567.
3. Tizard I. “Veterinary Immunology, 10^th edition, Saunders (2016).
4. Archer TM., et al. “Oral cyclosporine treatment in dogs: a review of the literature”. Journal of Veterinary Internal Medicine 28 (2014): 1-20.
5. Bobadilla NA and Gamba G. “New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone”. American Journal of Physiology-Renal Physiology 1 (2007): F2-F9.
6. Burdmann EA., et al. “Cyclosporine nephrotoxicity”. Seminars in Nephrology 5 (2003): 465-476.
7. Callan MB., et al. “Multiple papillomavirus‐associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine”. Veterinary Dermatology 16 (2005): 338-345.
8. Thacker EL. “Immunomodulators, immunostimulants, and immunotherapies in small animal veterinary medicine”. Veterinary Clinics of North America: Small Animal Practice 40 (2010): 473-483.
9. Blackwood L., et al. “Multicentric lymphoma in a dog after cyclosporine therapy”. Journal of Small Animal Practice 5 (2004): 259-262.
10. Gray LL., et al. “The effect of ketoconazole on whole blood and skin ciclosporin concentrations in dogs”. Veterinary Dermatology 24 (2013): 118-125e27-8.
11. Palmeiro BS. “Cyclosporine in veterinary dermatology”. Veterinary Clinics of North America: Small Animal Practice 43 (2013): 153-171.
12. Barnas JL., et al. “B cell targeted therapies in autoimmune disease”. Current Opinion in Immunology 61 (2019): 92-99.
13. Raef HS., et al. “Gene Expression Analysis in Four Dogs with Canine Pemphigus Clinical Subtypes Reveals B Cell Signatures and Immune Activation Pathways Similar to Human Disease”. Frontier Medicines 8 (2021): 1740.
14. Kim J., et al. “The treatment of pemphigus vulgaris and pemphigus foliaceus”. In: Murrell, D.F, editor. Blistering Diseases: Clinical Features, Pathogenesis, Treatment. Berlin: Springer (2015): 523-531.
15. Cattran DC., et al. “Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations”. Kidney International12 (2007): 1429-1447.
16. Xiao Z., et al. “Mechanisms of cyclosporine-induced renal cell apoptosis: a systematic review”. American Journal of Nephrology 1 (2013): 30-40.
17. Ihrke PJ., et al. “Pemphigus foliaceus in dogs: A review of 37 cases”. Journal of the American Veterinary Medical Association 186 (1985): 59-66.
18. Rosenkrantz WS. “Pemphigus: Current therapy”. Veterinary Dermatology 15 (2004): 90-98.
19. Kridin K. “Emerging treatment options for the management of pemphigus vulgaris”. Therapeutics and Clinical Risk Management 14 (2018): 757-778.
20. Lee JH., et al. “Urinary Concentration Defect and Renal Glycosuria in Cyclosporine-treated Rats”. Electrolyte and Blood Press1 (2020): 1-9.

Citation

Citation: Raguvaran Raja., et al. “Comparative Assessment of Efficacy of Prednisolone and Cyclosporine in Canine Pemphigus Complex".Acta Scientific Veterinary Sciences 6.2 (2024): 100-103.

Copyright

Copyright: © 2024 Raguvaran Raja., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.